AI-generated summary
This study protocol describes a planned randomized, double-blind trial in adults with stable non-segmental vitiligo, comparing crisaborole ointment plus 308-nm excimer laser with vehicle plus laser on paired lesions within each patient. The authors state the primary outcome will be the proportion of lesions achieving at least 75% improvement in the VASI/F-VASI score at the end of 24 weeks. No results are reported, as this is a protocol.
- Who or what was studied
- Adults aged 18 to 65 years with stable non-segmental vitiligo and at least two comparable symmetrical lesions
- Wavelengths
- 308 nm
- Limits stated in the abstract
- This is a study protocol, so no efficacy or safety results are reported, and the trial is single-center.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.